UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including ...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.

The interleukin-17 (IL-17) family cytokines are strong inducers of inflammation and help to protect us against invading pathogens. However, they also have a dark side and contribute to the tissue ...

Patients with psoriatic arthritis exhibit high levels of both IL-17A and IL-17F cytokines in the synovium. Bimekizumab, a biologic that targets both IL-17A and IL-17F, was recently approved for the ...

Mercer County Towing and Recovery sent in a picture of a downed power line on IL-17 east of Aledo. Additionally in Iowa City, MidAmerican Energy's power outage map said that approximately 1,900 ...

Learn how targeted therapy and advanced blood analysis transformed treatment for erthyroderma, a rare inflammatory skin ...